GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (FRA:4NX1) » Definitions » EV-to-Revenue

Lumos Pharma (FRA:4NX1) EV-to-Revenue : 8.12 (As of May. 21, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Lumos Pharma's enterprise value is €16.57 Mil. Lumos Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €2.04 Mil. Therefore, Lumos Pharma's EV-to-Revenue for today is 8.12.

The historical rank and industry rank for Lumos Pharma's EV-to-Revenue or its related term are showing as below:

FRA:4NX1' s EV-to-Revenue Range Over the Past 10 Years
Min: -3223.32   Med: 2.23   Max: 1180.68
Current: -5.43

During the past 13 years, the highest EV-to-Revenue of Lumos Pharma was 1180.68. The lowest was -3223.32. And the median was 2.23.

FRA:4NX1's EV-to-Revenue is ranked better than
96.26% of 1043 companies
in the Biotechnology industry
Industry Median: 8.21 vs FRA:4NX1: -5.43

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-21), Lumos Pharma's stock price is €7.20. Lumos Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.24. Therefore, Lumos Pharma's PS Ratio for today is 29.51.


Lumos Pharma EV-to-Revenue Historical Data

The historical data trend for Lumos Pharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma EV-to-Revenue Chart

Lumos Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1,179.89 -157.98 -24.48 -4.74

Lumos Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.76 -8.21 -6.72 -4.74 -

Competitive Comparison of Lumos Pharma's EV-to-Revenue

For the Biotechnology subindustry, Lumos Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumos Pharma's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumos Pharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lumos Pharma's EV-to-Revenue falls into.



Lumos Pharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Lumos Pharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=16.571/2.04
=8.12

Lumos Pharma's current Enterprise Value is €16.57 Mil.
Lumos Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lumos Pharma  (FRA:4NX1) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Lumos Pharma's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=7.20/0.244
=29.51

Lumos Pharma's share price for today is €7.20.
Lumos Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.24.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lumos Pharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Pharma (FRA:4NX1) Business Description

Traded in Other Exchanges
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

Lumos Pharma (FRA:4NX1) Headlines

No Headlines